SAMN47221409
External Id
dbGaP
INSDC center name
2025-03-05T06:03:42.437Z
INSDC first public
2025-04-26T20:31:38.487Z
INSDC last update
live
INSDC status
Generic
NCBI submission model
Generic.1.0
NCBI submission package
DNA/RNA
analyte type
NCI_NSCLC_RefractoryPDL1Therapy
biospecimen repository
CNTZWD91C.01
biospecimen repository sample id
Blood
body site
phs003295
gap_accession
1
gap_consent_code
DS-CA
gap_consent_short_name
7556540
gap_sample_id
5607333
gap_subject_id
No
is tumor
Homo sapiens
http://purl.obolibrary.org/obo/NCBITaxon_9606
organism
female
sex
Clinical Trial
study design
Durvalumab Plus Tremelimumab Alone or in Combination with Low-Dose or Hypofractionated Radiotherapy in Metastatic Non-Small-Cell Lung Cancer Refractory to Previous PD(L)-1 Therapy: an Open-Label, Multicentre, Randomised, Phase 2 Trial
study name
CNTZWD91C.01
submitted sample id
CNTZWD9
submitted subject id
NCI_NSCLC_RefractoryPDL1Therapy
submitter handle
Non-tumor DNA/RNA sample from Blood of a human female participant in the dbGaP study "Durvalumab Plus Tremelimumab Alone or in Combination with Low-Dose or Hypofractionated Radiotherapy in Metastatic Non-Small-Cell Lung Cancer Refractory to Previous PD(L)-1 Therapy: an Open-Label, Multicentre, Randomised, Phase 2 Trial"
title